Shares of drugmaker Sanofi (NASDAQ:SNY) failed to keep up with the broader market in 2013, and the stock is down nearly 8% year to date. Disappointing guidance and the recent FDA rejection of multiple sclerosis treatment Lemtrada have driven shares down. However, is the market being myopic? Could Sanofi be positioned for growth, and are its shares valued attractively compared to its Big Pharma peers? Analysts Max Macaluso and David Williamson discuss this dividend stock in the following video.
- Feb 11, 2014 at 9:30AM
- Health Care